{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:38:18Z","timestamp":1775713098054,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:00:00Z","timestamp":1146096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:p>Triclabendazole (TCBZ) is an halogenated benzimidazole (BZD) compound worldwide used to control immature and adult stages of the liver fluke <jats:italic>Fasciola hepatica<\/jats:italic>. The purpose of this investigation was to characterize <jats:italic>in vitro<\/jats:italic> the patterns of hepatic and ruminal biotransformation of TCBZ and its metabolites in sheep. TCBZ parent drug was metabolized into its sulphoxide (TCBZSO), sulphone (TCBZSO<jats:sub>2<\/jats:sub>) and hydroxy derivatives by sheep liver microsomes. The same microsomal fraction was also able to oxidize TCBZSO into TCBZSO<jats:sub>2<\/jats:sub> and hydroxy\u2010TCBZSO (HO\u2010TCBZSO). TCBZ sulphoxidation was significantly (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001) inhibited after inactivation of the flavin\u2010monooxygenase (FMO) system (77% inhibition) as well as in the presence of the FMO substrate methimazole (MTZ) (71% inhibition). TCBZ sulphoxidative metabolism was also reduced (24% inhibition, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05) by the cytochrome P450 inhibitor piperonyl butoxide (PB). The rate of TCBZSO conversion into TCBZSO<jats:sub>2<\/jats:sub> was also significantly inhibited by PB (55% inhibition), MTZ (52% inhibition) and also following FMO inactivation (58% inhibition). The data reported here indicate that the FMO is the main enzymatic pathway involved in TCBZ sulphoxidation (ratio FMO\/P450\u2003=\u20033.83\u2003\u00b1\u20031.63), although both enzymatic systems participate in a similar proportion in the sulphonation of TCBZSO to form the sulphone metabolite (ratio FMO\/P450\u2003=\u20031.31\u2003\u00b1\u20030.23). Additionally, ketoconazole (KTZ) did not affect TCBZ sulphoxidation but decreased (66% inhibition, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05) the formation of TCBZSO<jats:sub>2<\/jats:sub>. Similarly, inhibition of TCBZSO<jats:sub>2<\/jats:sub> production was observed after incubation of TCBZSO in the presence of KTZ and erythromycin (ETM). Conversely, thiabendazole (TBZ) and fenbendazole (FBZ) did not affect the oxidative metabolism of both incubated substrates. The sheep ruminal microflora was able to reduce the sulphoxide (TCBZSO) into the parent thioether (TCBZ). The ruminal sulphoreduction of the HO\u2010TCBZSO derivative into HO\u2010TCBZ was also demonstrated. The rate of sulphoreduction of HO\u2010TCBZSO was significantly (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05) higher than that observed for TCBZSO. The metabolic approach tested here contributes to the identification of the different pathways involved in drug biotransformation in ruminant species. These findings on the pattern of hepatic and ruminal biotransformation of TCBZ and its main metabolites are a further contribution to the understanding of the pharmacological properties of widely used anthelmintics in ruminants. Comprehension of TCBZ metabolism is critical to optimize its flukicidal activity.<\/jats:p>","DOI":"10.1111\/j.1365-2885.2006.00735.x","type":"journal-article","created":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T10:44:12Z","timestamp":1146221052000},"page":"213-223","source":"Crossref","is-referenced-by-count":54,"title":["Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep"],"prefix":"10.1111","volume":"29","author":[{"given":"G.","family":"VIRKEL","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"LIFSCHITZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"SALLOVITZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"PIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"LANUSSE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,4,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0742-8413(92)90096-P"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2885.1999.00194.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-4017(00)00320-4"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)83301-0"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2001.218.669"},{"key":"e_1_2_6_7_1","first-page":"159","article-title":"Pharmacokinetics of triclabendazole in cattle, sheep, goats, horses, ponies, donkeys, pigs and man","author":"Bogan J.","year":"1988","journal-title":"Proceedings of the 4th Congress of the European Association for Veterinary Pharmacology and Toxicology,\u00a0Budapest,\u00a0Hungary"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.113.14.315"},{"key":"e_1_2_6_9_1","article-title":"Efficacy of triclabendazole, its metabolites and other compounds in sheep","author":"B\u00fcscher G.","year":"1999","journal-title":"Proceedings of the International Conference of the World Association for the Advancement of Veterinary Parasitology"},{"key":"e_1_2_6_10_1","first-page":"376","article-title":"Resistance of sheep to pyrrolizidine alkaloids","volume":"42","author":"Craig A.","year":"1986","journal-title":"Israel Journal of Veterinary Medicine"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1978.tb00316.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(84)90600-3"},{"key":"e_1_2_6_13_1","first-page":"120","article-title":"Species differences in biotransformation : conventional models in unconventional animal species","volume":"48","author":"Fink\u2010Gremmels J.","year":"1996","journal-title":"Experimental and Toxicologic Pathology"},{"key":"e_1_2_6_14_1","first-page":"447","article-title":"In vitro sulfoxidation of albendazole by ovine liver microsomes: assay and frequency of various xenobiotics","volume":"47","author":"Galtier P.","year":"1986","journal-title":"American Journal of Veterinary Research"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1987.tb00078.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1992.tb00981.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1993.tb00157.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90583-I"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0034-5288(91)90082-Y"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510130204"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/03602539308993977"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03188780"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498259209046653"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498259309059382"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0034-5288(95)90106-X"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4894(91)90023-P"},{"key":"e_1_2_6_27_1","first-page":"160","article-title":"Chiral sulfoxidation of Albendazole by the flavin adenine dinucleotide\u2010containing and cytochrome P\u2010450 dependent monooxygenases from rat liver microsomes","volume":"23","author":"Moroni P.","year":"1995","journal-title":"Drug Metabolism and Disposition"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250400015285"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/tx00025a010"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/tvjl.2000.0561"},{"key":"e_1_2_6_31_1","first-page":"154","article-title":"Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes","volume":"23","author":"Newton D.","year":"1995","journal-title":"Drug Metabolism and Disposition"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(90)90206-Z"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00170.x"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(86)90557-5"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(86)90550-2"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2885.2002.00365.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(85)90442-7"},{"key":"e_1_2_6_38_1","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3109\/00498258709167408","article-title":"Sulphoxidation of albendazole by the FAD\u2010containing and cytochrome P450 dependent mono\u2010oxygenases from pig liver microsomes","volume":"17","author":"Souhaili El Amri H.","year":"1987","journal-title":"Xenobiotica"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182000077428"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004360050122"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2885.2002.00373.x"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.5.536"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1993.tb00291.x"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498259609050258"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/rvsc.1998.0239"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2885.2006.00735.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2885.2006.00735.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T01:15:19Z","timestamp":1697073319000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2885.2006.00735.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,27]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1111\/j.1365-2885.2006.00735.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2885.2006.00735.x","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,27]]}}}